[DOI] [PMC free article] [PubMed] [Google Scholar] 21.Yang X., Deignan J.L., Qi H., Zhu J., Qian S., Zhong J., Torosyan G., Majid S., Falkard B., Kleinhanz R.R., et al
#GLP1 #Semaglutide #ShilingPharma #DrugDelivery #Innovation #ObesityCare #Biopharma #ClinicalTrials #MedTech #ChinaPharma #PeptideTherapy #FutureOfMedicine Semaglutide is a large molecule
The interventions start with lifestyle changes, however for a large portion of individuals especially those with familial history and or decades or metabolic dysfunction, medications are necessary
Cognitive behavioral therapy remains the first-line treatment with the strongest evidence base
In this context, the authors of these guidelines recommend the use of the Statin-Associated Muscle Symptom Clinical Index (SAMS-CI) for objective assessment whether reported muscle pains are associated with statin treatment [412] (Table XXXIX)
Prioritise protein intake